ArticleNature cancer2021
Downregulation of the FTO m
Open access · bronzeAbstract read
In one paragraph
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 74 citations in OpenAlex.
- Methylation marks breast cancer metastasis: The roles of mThe Journal of biological chemistry · 2026Review
- RNA modifications in cancer and their detection: a review.Japanese journal of clinical oncology · 2026Review
- MOncogene · 2026Article
- Targeting FTO shows therapeutic potential in esophageal squamous cell carcinoma by modulating microRNA biogenesis.Oncogene · 2026Article
- Mitochondrial uncoupling inhibits serine catabolismCancer biology & medicine · 2026Article
- The AHCY-adenosine complex rewires mRNA methylation to enhance fatty acid biosynthesis and tumorigenesis.Cell research · 2026Article
- The Regulatory Role of mCells · 2026Review
- RNA modification systems as therapeutic targets.Nature reviews. Drug discovery · 2026Review
- Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance.Frontiers in immunology · 2026Review
- Anoikis resistance and cancer.BMC cancer · 2025Review
- Decoding epithelial regeneration in the cornea: multi-omic analysis reveals cellular plasticity as central mechanism.Cellular & molecular biology letters · 2025Article
- K88 acetylation of FTO increases its RNA mOncogene · 2025Article
- FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia.Science advances · 2025Article
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2025Review
- The Role of Fat Mass and Obesity-Associated (FTO) Gene in Non-Small Cell Lung Cancer Tumorigenicity and EGFR Tyrosine Kinase Inhibitor Resistance.Biomedicines · 2025Article
- The epigenetic landscape of brain metastasis.Oncogene · 2025Review
- Review
- Alteration of mMolecules (Basel, Switzerland) · 2025Article
- FDX1 overexpression inhibits the growth and metastasis of clear cell renal cell carcinoma by upregulating FMR1 expression.Cell death discovery · 2025Article
- Upregulation of circGDI2 inhibits tumorigenesis by stabilizing the expression of RNA m6A demethylase FTO in oral squamous cell carcinoma.Non-coding RNA research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
38 authors at 12 institutions in 5 countries.
Jana Jeschke *Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Evelyne Collignon *Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0001-7617-5905
Clémence Al Wardi *Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Mohammad Krayem *Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, ULB, Brussels, Belgium.
Martin BizetLaboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Yan JiaLaboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Soizic GaraudMolecular Immunology Laboratory, Institut Jules Bordet, ULB, Brussels, Belgium.
Zéna WimanaLaboratory of Oncology and Experimental Surgery, Institut Jules Bordet, ULB, Brussels, Belgium.
Emilie CalonneLaboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Bouchra HassabiLaboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Renato MorandiniLaboratory of Oncology and Experimental Surgery, Institut Jules Bordet, ULB, Brussels, Belgium.
Rachel DeplusLaboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Pascale PutmansLaboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Gaurav DubeLaboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Nitesh Kumar SinghLaboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Alexander KochDepartment of Pathology, Maastricht UMC, Maastricht, the Netherlands.
Kateryna ShostakLaboratory of Medical Chemistry, GIGA Stem Cells, University of Liège, Liège, Belgium.
Lara RizzottoTrace, LKI Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Robert L RossRieveschl Laboratories for Mass Spectrometry, Department of Chemistry, University of Cincinnati, Cincinnati, OH, USA.
Christine DesmedtBreast Cancer Translational Research Laboratory, Institut Jules Bordet, U-CRC, ULB, Brussels, Belgium.ORCID http://orcid.org/0000-0002-5223-5579
Yacine BarecheBreast Cancer Translational Research Laboratory, Institut Jules Bordet, U-CRC, ULB, Brussels, Belgium.ORCID http://orcid.org/0000-0002-7208-6494
Françoise RothéBreast Cancer Translational Research Laboratory, Institut Jules Bordet, U-CRC, ULB, Brussels, Belgium.
Jacqueline Lehmann-ChePathophysiology of Breast Cancer Team, Université de Paris, INSERM U976, HIPI, Paris, France.ORCID http://orcid.org/0000-0001-6685-3354
Martine Duterque-CoquillaudUniversité Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-UMR-S 1277, CANTHER, Lille, France.
Xavier LeroyUniversité Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-UMR-S 1277, CANTHER, Lille, France.
Gerben MenschaertBiobix, Laboratory of Bioinformatics and Computational Genomics, Ghent University, Ghent, Belgium.
Luis TeixeiraPathophysiology of Breast Cancer Team, Université de Paris, INSERM U976, HIPI, Paris, France.ORCID http://orcid.org/0000-0003-1049-9661
Mingzhou GuoDepartment of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing, China.
Patrick A LimbachRieveschl Laboratories for Mass Spectrometry, Department of Chemistry, University of Cincinnati, Cincinnati, OH, USA.
Pierre CloseLaboratory of Cancer Signaling, GIGA Stem Cells, University of Liège, Liège, Belgium.ORCID http://orcid.org/0000-0002-8844-9616
Alain ChariotLaboratory of Medical Chemistry, GIGA Stem Cells, University of Liège, Liège, Belgium.
Eleonora LeucciTrace, LKI Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Ghanem GhanemLaboratory of Oncology and Experimental Surgery, Institut Jules Bordet, ULB, Brussels, Belgium.
Bi-Feng YuanCollege of Chemistry and Molecular Sciences, Wuhan University, Wuhan, China.ORCID http://orcid.org/0000-0003-1107-5385
Karen Willard-GalloMolecular Immunology Laboratory, Institut Jules Bordet, ULB, Brussels, Belgium.ORCID http://orcid.org/0000-0002-1150-1295
Christos SotiriouBreast Cancer Translational Research Laboratory, Institut Jules Bordet, U-CRC, ULB, Brussels, Belgium.ORCID http://orcid.org/0000-0002-5745-9977
Jean-Christophe MarineLaboratory for Molecular Cancer Biology, VIB, KU Leuven, Leuven, Belgium.
François FuksLaboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium. ffuks@ulb.ac.be.ORCID http://orcid.org/0000-0003-4637-7287
Université Libre de Bruxelles · BEInstitut Jules Bordet · BEUniversity of Liège · BECentre National de la Recherche Scientifique · FRInserm · FRUniversity of Cincinnati · USVIB-KU Leuven Center for Cancer Biology · BEChinese PLA General Hospital · CNGhent University · BEKU Leuven · BEMaastricht University Medical Centre · NLWuhan University · CN
Funding
UPLC for Enhanced Mass Spectrometry of Modified RNAsR01GM058843 · NIGMS · UNIVERSITY OF CINCINNATI · PI LIMBACH, PATRICK A · 1999 to 2025
$5.1MMass Spectrometry of Ribosomal RNA:Protein InteractionsR56GM058843 · NIGMS · UNIVERSITY OF CINCINNATI · PI LIMBACH, PATRICK A · 2009 to 2009
$330kNIGMS NIH HHS R01 GM058843NIGMS NIH HHS R56 GM058843
Abstract
Post-transcriptional modifications of RNA constitute an emerging regulatory layer of gene expression. The demethylase fat mass- and obesity-associated protein (FTO), an eraser of N
Indexed as
Neoplasms, Glandular and EpithelialRNAAlpha-Ketoglutarate-Dependent Dioxygenase FTOAnimalsDown-RegulationEpithelial-Mesenchymal TransitionHumansMiceAlpha-Ketoglutarate-Dependent Dioxygenase FTOFTO protein, humanFTO protein, mouseRNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.